News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Biologics, Inc. (NC) Announces Collaborative Program Partnership For YERVOY® (Ipilimumab) Patients


12/9/2013 9:54:08 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

CARY, N.C.--(BUSINESS WIRE)--Biologics, Inc. is pleased to announce the launch of the YERVOY® (ipilimumab) Education & Support (Y.E.S.) Program - designed by Biologics and sponsored by Bristol-Myers Squibb to provide a high-touch support system for patients during their YERVOY therapy. YERVOY is an IV prescription medicine, approved in March 2011, for use in adults to treat melanoma (a kind of skin cancer) that has spread or cannot be removed by surgery. It is not known if YERVOY is safe and effective in patients less than 18 years of age.

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES